Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 06 Sep 2018
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2018 Planned End Date changed from 15 Apr 2020 to 31 Dec 2020.
- 11 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2019.